ISTH 2023 | Antithrombotic effects of isoquercetin in sickle cell disease
Bindu Parachalil Gopalan, PhD, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, discusses a recent analysis of the antithrombotic effects of isoquercetin in patients with sickle cell disease (SCD) who participated in a randomized placebo-controlled Phase II trial (NCT04514510). Dr Gopalan shares the rationale behind this trial and further discusses the results, highlighting the effects of isoquercetin in reducing the hypercoagulable state in SCD. Future studies with higher doses of this agent are underway. This interview took place at the 31st Congress of the International Society on Thrombosis and Haemostasis (ISTH), held in Montréal, Canada.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
